CM Management LLC Purchases 200,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

CM Management LLC boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 700,000 shares of the biotechnology company's stock after buying an additional 200,000 shares during the quarter. CM Management LLC owned approximately 0.46% of Heron Therapeutics worth $1,071,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Anfield Capital Management LLC grew its position in shares of Heron Therapeutics by 5.6% in the fourth quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock valued at $182,000 after purchasing an additional 6,264 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Heron Therapeutics by 21.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company's stock valued at $90,000 after buying an additional 7,927 shares during the last quarter. King Wealth Management Group grew its holdings in Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company's stock valued at $46,000 after buying an additional 8,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock worth $1,692,000 after buying an additional 9,418 shares during the period. Finally, Glenmede Trust Co. NA lifted its holdings in shares of Heron Therapeutics by 49.6% during the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company's stock worth $63,000 after buying an additional 10,578 shares during the last quarter. Institutional investors own 80.01% of the company's stock.

Remove Ads

Heron Therapeutics Price Performance

Shares of HRTX traded up $0.12 on Wednesday, reaching $2.41. 1,760,171 shares of the stock traded hands, compared to its average volume of 1,877,406. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The firm has a market cap of $367.12 million, a price-to-earnings ratio of -13.39 and a beta of 1.55. The stock's 50-day moving average price is $1.80 and its 200-day moving average price is $1.73.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. As a group, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on HRTX. Needham & Company LLC restated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.